Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset

Human Molecular Genetics

Volumn 23, Issue 8, 2014, Pages 1957-1963

  Gordon, Adam S ^a   Tabor, Holly K ^b,n   Johnson, Andrew D ^c   Snively, Beverly M ^d   Assimes, Themistocles L ^e   Auer, Paul L ^f   Ioannidis, John P A ^e   Peters, Ulrike ^f   Robinson, Jennifer G ^g   Sucheston, Lara E ^h   Wang, Danxin ⁱ   Sotoodehnia, Nona ^b   Rotter, Jerome I ^k   Psaty, Bruce M ^b,m   Jackson, Rebecca D ^j   Herrington, David M ^d   O'donnell, Christopher J ^c   Reiner, Alexander P ^a,f   Rich, Stephen S ^l   Rieder, Mark J ^a   Bamshad, Michael J ^a,b   Nickerson, Deborah A ^a   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF IOWA   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k HARBOR UCLA MEDICAL CENTER   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

^m CENTER FOR HEALTH STUDIES   (United States)

ⁿ SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7;

ALLELE; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; EXOME; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; STOP CODON;

CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXOME; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84897848726     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt588     Document Type: Article

References (22)

1. Wang, L., McLeod, H.L. and Weinshilboum, R.M. (2011) Genomics and drug response. N. Engl. J. Med., 364, 1144-1153.
2. Nelson, M.R., Wegmann, D., Ehm, M.G., Kessner, D., St Jean, P., Verzilli, C., Shen, J., Tang, Z., Bacanu, S.-A., Fraser, D. et al. (2012) Anabundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 10.1126/science.1217876.
3. Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
4. Nelson, D.R., Zeldin, D.C., Hoffman, S.M.G., Maltais, L.J., Wain, H.M. and Nebert, D.W. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and humangenomes, including nomenclature recommendations forgenes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1-18.
5. Paré, G., Mehta, S.R., Yusuf, S., Anand, S.S., Connolly, S.J., Hirsh, J., Simonsen, K., Bhatt, D.L., Fox, K.A.A. and Eikelboom, J.W. (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med., 363, 1704-1714.
6. International Warfarin Pharmacogenetics ConsortiumKlein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., Lee, M.-T.M., Limdi, N.A., Page, D., Roden, D.M. et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360, 753-764.
7. Meckley, L.M., Wittkowsky, A.K., Rieder, M.J., Rettie, A.E. and Veenstra, D.L. (2008) An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb. Haemost., 100, 229-239.
8. Fu, W., O'Connor, T.D., Jun, G., Kang, H.M., Abecasis, G., Leal, S.M., Gabriel, S., Altshuler, D., Shendure, J., Nickerson, D.A. et al. (2012) Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 10.1038/nature11690.
9. González-Pérez, A. and López-Bigas, N. (2011) Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am. J. Hum. Genet., 88, 440-449.
10. Cooper, G.M., Stone, E.A. and Asimenos, G. NISC Comparative Sequencing Program, Green, E.D., Batzoglou, S. and Sidow, A. (2005) Distribution and intensity of constraint in mammalian genomic sequence. Genome Res., 15, 901-913.
11. Cooper, G.M., Goode, D.L., Ng, S.B., Sidow, A., Bamshad, M.J., Shendure, J. and Nickerson, D.A. (2010) Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat. Methods, 7, 250-251.
12. Grantham, R. (1974) Amino acid difference formula to help explain protein evolution. Science, 185, 862-864.
13. Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A.L., Deloukas, P., Daly, A.K., Park, B.K., Aarons, L., Ogungbenro, K. et al. (2012) The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br. J. Clin. Pharmacol., 73, 66-76.
14. Dickmann, L.J., Locuson, C.W., Jones, J.P. and Rettie, A.E. (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol. Pharmacol., 65, 842-850.
15. Williams, P.A., Cosme, J., Ward, A., Angove, H.C., Matak Vinković, D. and Jhoti, H. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 424, 464-468.
16. Davies, C., Witham, K., Scott, J.R., Pearson, A., DeVoss, J.J., Graham, S.E. and Gillam, E.M.J. (2004) Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9). Drug Metab. Dispos., 32, 431-436.
17. Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.S., Johnson, J.A., Roden, D.M., Klein, T.E. and Shuldiner, A.R. Clinical Pharmacogenetics Implementation Consortium. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther., 90, 328-332.
18. Rettie, A.E. and Tai, G. (2006) The pharmocogenomics of warfarin: closing in on personalized medicine. Mol. Interv., 6, 223-227.
19. Tennessen, J.A., Bigham, A.W., O'Connor, T.D., Fu, W., Kenny, E.E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G. et al. (2012) Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science, 337, 64-69.
20. Marth, G.T., Yu, F., Indap, A.R., Garimella, K., Gravel, S., Leong, W.F., Tyler-Smith, C., Bainbridge, M., Blackwell, T., Zheng-Bradley, X. et al. (2011) The functional spectrum of low-frequency coding variation. Genome Biol., 12, R84.
21. Ramsey, L.B., Bruun, G.H., Yang, W., Trevino, L.R., Vattathil, S., Scheet, P., Cheng, C., Rosner, G.L., Giacomini, K.M., Fan, Y. et al. (2012) Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome. Res., 22, 1-8. doi: 10.1101/gr.129668.111.
22. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M. et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res., 20, 1297-1303.